TargetBeta
CD28
CD28 molecule · CD molecules
7 programs in company-led studies act on CD28, from 6 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 22 running | FOLH1 | a judged reading |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD3E, GPRC5D | the studies' text |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | CytoCares | phase 1 | 44 running | CD19, CD3E | NCIt |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 21 running | CD276 | NCIt |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | Rondo Therapeutics | phase 1 | 11 running | NECTIN4 | NCIt |
| HLX3901 | Fosun Pharma | phase 1 | 11 running | CD3E, DLL3 | the company's pipeline |
| HLX3902 | Fosun Pharma | phase 1 | 11 running | CD3E, STEAP1 | the company's pipeline |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Multiple Myeloma, 1 program
- Ovarian Neoplasms, 1 program
- Prostatic Neoplasms, 1 program
- Prostatic Neoplasms, Castration-Resistant, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 21, 2027Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 · Johnson & Johnson · phase 3 · NCT06095089
- Jun 29, 2027HLX3902 · Fosun Pharma · phase 1 · NCT07533708
- Sep 10, 2027Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312 · CytoCares · phase 1 · NCT07177911
- May 30, 2028HLX3901 · Fosun Pharma · phase 1 · NCT07416695
- Dec 2028Anti-B7-H3/CD28 Bispecific Antibody XmAb808 · Xencor · phase 1 · NCT07593092
- Feb 28, 2029Anti-nectin-4/CD28 Bispecific Antibody RNDO-564 · Rondo Therapeutics · phase 1 · NCT07218003
- Sep 30, 2033REGN17372 · Regeneron Pharmaceuticals · phase 2 · NCT07455851
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.